

Generex Announces Upgrade to OTCQB® Venture Market

November 30, 2017 - MIRAMAR, Fla. Generex Biotechnology Corporation (GNBT) (<http://www.otcmarkets.com/stock/GNBT/quote>) (www.generex.com) today announced that trading in its common stock will be upgraded to the OTCQB® Venture Market on November 30, 2017 after a successful application to up-list from the OTC Pink Market.

OTCQB® membership provides enhanced investor benefits, including more stringent reporting standards, increased analyst coverage and access to news services, as well as more comprehensive compliance requirements. Generex President & Chief Executive Officer, Joe Moscato, commented: "We anticipate that our return to the OTCQB® Venture Market will increase our visibility in the investment community and reinvigorate our stockholder base. It is an important step in the implementation of Generex's repurposed business plan."

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new

information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contact:

Generex

Joseph Moscato, 646-599-6222

or

Generex Biotechnology Corporation

Todd Falls, 800-391-6755, Extension 222

investor@generex.com